Summit Therapeutics (SMMT) Scheduled to Post Quarterly Earnings on Wednesday

Summit Therapeutics (NASDAQ:SMMT) is set to release its earnings data before the market opens on Wednesday, May 1st. Analysts expect Summit Therapeutics to post earnings of ($0.06) per share for the quarter. Persons that wish to register for the company’s earnings conference call can do so using this link.

Summit Therapeutics (NASDAQ:SMMT) last issued its quarterly earnings results on Tuesday, February 20th. The company reported ($0.05) earnings per share (EPS) for the quarter. The company had revenue of $0.20 million for the quarter. On average, analysts expect Summit Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Summit Therapeutics Stock Up 2.6 %

Summit Therapeutics stock traded up $0.10 during trading on Tuesday, reaching $3.98. The stock had a trading volume of 536,377 shares, compared to its average volume of 2,145,503. Summit Therapeutics has a 52-week low of $1.33 and a 52-week high of $5.22. The business has a 50 day moving average price of $4.03 and a 200 day moving average price of $3.20. The company has a quick ratio of 9.30, a current ratio of 9.30 and a debt-to-equity ratio of 1.29. The stock has a market cap of $2.79 billion, a PE ratio of -2.54 and a beta of -1.21.

Analyst Upgrades and Downgrades

Separately, Stifel Nicolaus assumed coverage on shares of Summit Therapeutics in a research note on Tuesday, March 26th. They issued a “buy” rating and a $8.00 price target for the company.

Insiders Place Their Bets

In related news, CFO Ankur Dhingra acquired 100,000 shares of the business’s stock in a transaction on Tuesday, March 26th. The shares were bought at an average price of $3.75 per share, with a total value of $375,000.00. Following the completion of the acquisition, the chief financial officer now owns 354,958 shares in the company, valued at $1,331,092.50. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In related news, CFO Ankur Dhingra acquired 100,000 shares of the business’s stock in a transaction on Tuesday, March 26th. The shares were bought at an average price of $3.75 per share, with a total value of $375,000.00. Following the completion of the acquisition, the chief financial officer now owns 354,958 shares in the company, valued at $1,331,092.50. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Mahkam Zanganeh acquired 30,000 shares of the business’s stock in a transaction on Tuesday, March 26th. The shares were bought at an average cost of $3.75 per share, for a total transaction of $112,500.00. Following the acquisition, the chief executive officer now owns 30,000 shares of the company’s stock, valued at approximately $112,500. The disclosure for this purchase can be found here. 83.70% of the stock is owned by corporate insiders.

About Summit Therapeutics

Summit Therapeutics Inc, a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections.